MilliporeSigma on February 7 announced a corporate reorganization that combines several business units, with a strong focus on improving the company's offerings in the contract development and manufacturing organization (CDMO) segment.
Chief among the changes is the formation of a new Life Science Services business unit that consolidates the company's offerings in CDMO and contract testing services. The CDMO business will include traditional modalities like monoclonal antibodies (mAbs) and high-potency active pharmaceutical ingredients (HP-APIs), as well as novel technologies such as antibody drug conjugates (ADCs) and viral and gene therapies (VGTs).
The Life Sciences Services division will include sales and marketing, research and development, manufacturing, and supply chain operations, according to MilliporeSigma. The division will be led by Dirk Lange, who is joining the company on February 15 from KBI Biopharma, where he has been president and CEO.
In other moves, MilliporeSigma is combining its Research Solutions and Applied Solutions businesses into a single organization, Science and Lab Solutions (SLS). This business will offer products that include reagents, consumables, devices, instruments, software, and services for scientific discovery, as well as lab water instruments, consumables and services, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. The business will be led by Jean-Charles Wirth, who is currently head of Applied Solutions.
In the company's Integrated Supply Chain and Operations (ISCO), division chief executive Christos Ross is retiring effective March 31, with his successor to be Ivan Donzelot, who will join the company from 3M in Europe. Finally, MilliporeSigma's Process Solutions (PS) division will continue to be led by Andrew Bulpin and will maintain its focus on pharmaceutical development and manufacturing.